Baylor Research Institute

Schering Corporation

Institut National De La Sante Et De La Recherche Medicale

Other

Centre National De La Recherche Scientifique

Université´ D'aix-Marseille

Agence Nationale De Recherches Sur Le Sida Et Les Hepatitis Virales

Inserm (institut National De La Sante Et De La Recherche Medicale)

Inserm

Jacques F Banchereau

Gerard Zurawski

Sandra M Zurawski

SangKon Oh

Anne-Laure Flamar

Eynav Klechevsky

Yves Levy

Anna Karolina Palucka

Monica Montes

Sangkon Oh

Dapeng Li

Virginia Pascual

Maria Virginia Pascual

Serge J E Lebecque

Keiko Akagawa

Peter Klucar

Christophe Caux

Odile Djossou

Francois Fossiez

Patrick Blanco

Pierre Golstein

Eric Rouvier

Kiley Prilliman

Elizabeth Esther Mary Bates

Jean-Pierre Gorvel

Hideki Ueno

Blandine Marie De Saint-Vis

Lee Roberts

Lynda B Bennett

Amanda Cobb

Bali Pulendran

Holly Mead

Christopher W Cutler

Anna Martirosyan

Ling Ni

Helene Dutartre

Gerald Zurawski

Frederic Berard

Eve-Marie Neidhart-Berard

Louis M Sloan

Mahyar Nouri-Shirazi

Damien Chaussabel

Aynav Klechevsky

John E Connolly

The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Fusion proteins comprising an anti-CD40 antibody and cancer antigens

The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1&#x3b2;.

Compositions and methods for the systemic treatment of arthritis

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Nucleic acids encoding anti-CD40 antibodies

Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides

Anti-CD40 antibodies

Method of making an anti-CD40 antibody

Disclosed are compositions and methods for treatment of breast cancer. Disclosed methods and compositions include dendritic cells loaded with cyclin B1 and WT-1 peptide antigens for immunotherapy. These dendritic cell vaccines are administered alone or in combination with other cancer therapies to improve outcomes. Disclosed methods also involve the use of therapeutic agents, such as anakinra, that block the IL-1 inflammation pathway. These agents are used in combination with chemotherapy and/or immunotherapy in treating breast cancer.

Methods and compositions for treating breast cancer with dendritic cell vaccines

Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.

Compositions and methods to immunize against hepatitis C virus

Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-&#x3b1;), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS).

Dendritic cell vaccines

Growing community of inventors

Dallas, TX, United States of America

Jacques F Banchereau